Sputnik V receives DCGI approval, makes it 3rd corona vaccine for India

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

India on Monday approved Russian jab Sputnik V as the third Covid-19 vaccine for restricted use in the country. The vaccine was developed by the Gamaleya Research Institute (GRI) of Russia, and funded and promoted outside by the Russian Direct Investment Fund (RDIF).

In India, the RDIF's partner is Dr Reddy's Laboratories, which conducted clinical trials - mandatory for approval - India. Sputnik-V became the first vaccine to be announced last year for protection against Covid-19.

It works on complex biotechnology in which another virus is employed to carry the DNA code required for triggering an immune response in human cells. Sputnik V's approval has come at a time when the country is reeling under a shortage of existing two vaccines - Covishield and Covaxin.

India has a combined production capacity of around 6.40 crore doses a month of the two approved vaccines in a month. Covishield-maker Serum Institute of India (SII) is shouldering the major burden as the other vaccine-manufacturer, the Bharat Biotech has a limited capacity of 40 lakh doses a month.

Several states have flagged in recent days that both Covishield and Covaxin are in short supply. Reports of vaccination centres from Varanasi in Uttar Pradesh to Mumbai in Maharashtra appeared last week.

Vaccine shortage became an issue of a political fight between the Centre and the Opposition-ruled governments in the backdrop of the second wave of Covid-19 pandemic wreaking havoc in at least 10 states. Maharashtra, Delhi, Chhattisgarh, Punjab, Madhya Pradesh, Kerala, and Uttar Pradesh are among severely impacted states.

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

Sputnik V, named after the first Soviet space satellite, showed a better efficacy during trials compared to the vaccines already in use in India. Both Covishield and Covaxin showed the efficacy of around 81 per cent in the trials, Sputnik V returned with 91-92 per cent efficacy.

On the production front, the Russian Direct Investment Fund (RDIF) has tied up with Indian pharmaceutical firms such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the manufacturing the vaccine doses.

These firms jointly have an annual production capacity of 850 million doses for Sputnik V. This makes Sputnik V's approval a big shot in the arm in the fight against the Covid-19 pandemic.

It is expected that the doses of the Sputnik V vaccine will be available at vaccination centres by June this year. There are at least four more vaccines that are expected to get approval from the Drug Controller General of India (DCGI) by the year-end.







Tags : #SputnikV #RussianVaccineforCorona #EfficacyofRussianVaccine #DrReddysLab #SerumInstituteofIndia #BharatBiotech #DCGI #LatestNewsonCOVIDVaccine13thApr

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024